Context Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings Results

Context Therapeutics (NASDAQ:CNTX) announced its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03, FiscalAI reports.

Context Therapeutics Trading Down 1.1%

Shares of NASDAQ CNTX traded down $0.03 during midday trading on Friday, reaching $2.31. The company’s stock had a trading volume of 164,528 shares, compared to its average volume of 1,373,775. Context Therapeutics has a one year low of $0.49 and a one year high of $3.62. The company has a market cap of $211.78 million, a price-to-earnings ratio of -5.49 and a beta of 1.57. The company has a 50 day moving average price of $2.62 and a 200 day moving average price of $1.90.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CNTX. Piper Sandler lifted their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th. Guggenheim reaffirmed a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Tuesday, March 24th. Wall Street Zen cut shares of Context Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.60.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CNTX. Quadrature Capital Ltd acquired a new stake in shares of Context Therapeutics during the 4th quarter valued at $68,000. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics in the 3rd quarter worth $100,000. State Street Corp raised its position in shares of Context Therapeutics by 8.5% during the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Context Therapeutics during the fourth quarter valued at $3,824,000. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.